A Randomized, Multicenter, Open-label, Phase 3 Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Subjects With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase III
Latest Information Update: 29 Jul 2018
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 13 Dec 2017 Status changed from not yet recruiting to recruiting.
- 15 Nov 2017 Planned initiation date changed from 15 Nov 2017 to 1 Dec 2017.
- 24 Aug 2017 Planned End Date changed from 30 Nov 2021 to 31 Aug 2022.